modelCodeineAndOtherNonOpioidAnalgesi
Extends from Pharmacolibrary.Drugs.ATC.N.N02AJ09.
Information
| name: | CodeineAndOtherNonOpioidAnalgesics |
| ATC code: | N02AJ09 | route: | oral |
| n-compartments | 1 |
Combination products containing codeine (a mild opioid analgesic and cough suppressant) with non-opioid analgesics are used for the relief of mild to moderate pain unresponsive to non-opioid analgesics alone. These combinations are often found in over-the-counter or prescription formulations for short-term management of pain. Codeine use is approved in certain countries, but its use is restricted or banned in pediatric populations and in some locations due to abuse potential and safety concerns.
Pharmacokinetics
Estimated pharmacokinetic parameters for an adult population based on literature for codeine-containing fixed-dose combination tablets administered orally. Model reflects typical values for codeine with non-opioids in healthy adults. No direct publication reporting full model PK for N02AJ09 combination product.
References
Goelen, N, et al., & Tack, J (2021). Effect of protein composition of enteral formula on gastric content volume during continuous feeding: A randomized controlled cross-over study in healthy adults. Clinical nutrition (Edinburgh, Scotland) 40(5) 2663–2672. DOI:10.1016/j.clnu.2021.03.021 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33933732
Velez de Mendizabal, N, et al., & Carleton, BC (2015). A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose. Clinical pharmacokinetics 54(10) 1083–1090. DOI:10.1007/s40262-015-0256-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25773480
Coller, JK, et al., & Somogyi, AA (2012). Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients. British journal of clinical pharmacology 74(5) 835–841. DOI:10.1111/j.1365-2125.2012.04256.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/22369095
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 initial generated model